These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20844085)

  • 1. P4 peptide therapy rescues aged mice from fatal pneumococcal sepsis.
    Rajam G; Bangert M; Hammons GM; Melnick N; Carlone GM; Sampson JS; Ades EW
    Clin Vaccine Immunol; 2010 Nov; 17(11):1823-4. PubMed ID: 20844085
    [No Abstract]   [Full Text] [Related]  

  • 2. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
    Xu JH; Dai WJ; Chen B; Fan XY
    Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and immunogenicity of capsular polysaccharide-surface adhesin A (PsaA) conjugate of Streptococcuspneumoniae.
    Lin H; Lin Z; Meng C; Huang J; Guo Y
    Immunobiology; 2010 Jul; 215(7):545-50. PubMed ID: 19880214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 28-aa pneumococcal surface adhesin A-derived peptide, P4, augments passive immunotherapy and rescues mice from fatal pneumococcal infection.
    Rajam G; Skinner J; Melnick N; Martinez J; Carlone GM; Sampson JS; Ades EW
    J Infect Dis; 2009 Apr; 199(8):1233-8. PubMed ID: 19265478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization.
    Roche AM; Weiser JN
    Infect Immun; 2010 May; 78(5):2231-9. PubMed ID: 20231407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.
    Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y
    Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P4-mediated antibody therapy in an acute model of invasive pneumococcal disease.
    Bangert M; Bricio-Moreno L; Gore S; Rajam G; Ades EW; Gordon SB; Kadioglu A
    J Infect Dis; 2012 May; 205(9):1399-407. PubMed ID: 22457294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A.
    Oliveira ML; Arêas AP; Campos IB; Monedero V; Perez-Martínez G; Miyaji EN; Leite LC; Aires KA; Lee Ho P
    Microbes Infect; 2006 Apr; 8(4):1016-24. PubMed ID: 16549380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies.
    Tai SS
    Crit Rev Microbiol; 2006; 32(3):139-53. PubMed ID: 16893751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides.
    Denoël P; Godfroid F; Hermand P; Verlant V; Poolman J
    Vaccine; 2011 Sep; 29(38):6451-3. PubMed ID: 21315695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model.
    Whaley MJ; Sampson JS; Johnson SE; Rajam G; Stinson-Parks A; Holder P; Mauro E; Romero-Steiner S; Carlone GM; Ades EW
    Vaccine; 2010 Apr; 28(18):3071-5. PubMed ID: 20206671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of splenectomy upon the course of experimental pneumococcal bacteraemia in rats and the efficacy of penicillin therapy.
    Bakker-Woudenberg IA; de Bos P; van Gerwen AL; van Leeuwen WB; Michel MF
    J Infect; 1982 Jan; 4(1):17-26. PubMed ID: 7185977
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody Response is More Likely to Pneumococcal Proteins Than to Polysaccharide After HIV-associated Invasive Pneumococcal Disease.
    Kantsø B; Green N; Goldblatt D; Benfield T
    J Infect Dis; 2015 Oct; 212(7):1093-9. PubMed ID: 25762789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reactivity of four monoclonal and two polyclonal antibodies raised against recombinant pneumococcal surface adhesin A.
    Werno AM; Lewis JG; George PM; Murdoch DR
    Hybridoma (Larchmt); 2012 Jun; 31(3):168-75. PubMed ID: 22741580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.
    Wang S; Li Y; Shi H; Scarpellini G; Torres-Escobar A; Roland KL; Curtiss R
    Infect Immun; 2010 Jul; 78(7):3258-71. PubMed ID: 20479086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravenous immunoglobulin administration to a patient with systemic lupus erythematosus and pneumococcal septicemia].
    Maltbaek N; Harreby MS; Thøgersen B
    Ugeskr Laeger; 1994 Jul; 156(27):4039-41. PubMed ID: 8066901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation.
    Voß F; Kohler TP; Meyer T; Abdullah MR; van Opzeeland FJ; Saleh M; Michalik S; van Selm S; Schmidt F; de Jonge MI; Hammerschmidt S
    Front Immunol; 2018; 9():2405. PubMed ID: 30405609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.